Brief: Dr. Lal Pathlabs Approved The Re-Designation Of Shankha Banerjee By Appointing Him As CEO With Effect From May 21, 2024.
March 17 (Reuters) - Dr. Lal PathLabs Ltd DLPA.NS :
* APPROVED THE RE-DESIGNATION OF SHANKHA BANERJEE BY
APPOINTING
HIM AS CEO WITH EFFECT FROM MAY 21, 2024.
Source text for Eikon: [ID: nNSE6BBmpx]
Further company coverage: DLPA.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dr. Lal PathLabs
See all newsBrief: Lal Pathlabs Says Unit Acquired Remaining 30% Equity Stake In Centrapath Labs Private Limited
India's Dr Lal PathLabs rises as Axis Securities initiates with 'buy'
India's Dr Lal PathLabs rises; analysts back SN Genelab deal
Brief: Lal Pathlabs Says Subsidiary Incorporated Dr Lal Pathlabs Indomed In Tashkent, Uzbekistan
India's Dr Lal PathLabs jumps to 4-year high after quarterly profit rise